Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders
Sven Ruf(Sanofi (France)), Aimo Kannt(Goethe University Frankfurt)
Cited by 26
Related Papers
Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction
|Nature Medicine|2017|493
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2
|Stem Cell Reports|2022|239
A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders
|Scientific Reports|2018|99
Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy
|Diabetes Care|2019|88
Activation of Adenosine Monophosphate—Activated Protein Kinase Reduces the Onset of Diet‐Induced Hepatocellular Carcinoma in Mice
|Hepatology Communications|2020|13